Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Internal Medicine (Tokyo, Japan)|March 29, 2021
Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related DiseaseSachi Okawa, Kammei Rai, Nobuharu Fujii, et al.
Molecular Cancer Therapeutics|May 29, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR MutationSachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor MicroenvironmentAtsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, et al.
Cancer Science|February 27, 2026
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung CancerTadahiro Kuribayashi, Jun Nishimura, Sachi Okawa, et al.
Respiratory Research|February 8, 2022
Identification of targetable kinases in idiopathic pulmonary fibrosisHisao Higo, Kadoaki Ohashi, Shuta Tomida, et al.
Lung Cancer (Amsterdam, Netherlands)|February 8, 2023
PD-1 blockade augments CD8+ T cell dependent antitumor immunity triggered by Ad-SGE-REIC in Egfr-mutant lung cancerTakamasa Nakasuka, Kadoaki Ohashi, Kazuya Nishii, et al.
Translational Lung Cancer Research|November 29, 2023
CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancerNaofumi Hara, Eiki Ichihara, Hirohisa Kano, et al.
Molecular Oncology|May 22, 2026
Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancerJun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, et al.
Cancer Science|January 7, 2021
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancersHiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, et al.
Cancer Immunology Research|July 8, 2022
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung CancerKazuya Nishii, Kadoaki Ohashi, Shuta Tomida, et al.
Pageof 3